Journal of cardiology · 2026
Comparison of clinical outcomes between biodegradable polymer sirolimus-eluting stents and durable polymer everolimus-eluting stents in octogenarian patients.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kushi Masaki, Ozaki Yuichi, Komatsu Keiya, Hikida Ryo, Komukai Kenichi, Katayama Yosuke, Satogami Keisuke, Takahata Masahiro, Wada Teruaki, Kashiwagi Manabu, Shiono Yasutsugu, Kuroi Akio, Yamano Takashi, Tanimoto Takashi, Kuki Shintaro, Ino Yasushi, Hayashi Yasushi, Kitabata Hironori, Tanaka Atsushi
Аннотация
BACKGROUND: Biodegradable polymer sirolimus-eluting stents (BP-SESs) have provided similar clinical outcomes including cardiac death, myocardial infarction (MI), and target lesion revascularization to second-generation durable polymer everolimus-eluting stents (DP-EESs). However, safety and efficacy of BP-SES in patients aged ≥80 years remain unknown. The aim of this study was to investigate the 1-year clinical outcomes between BP-SES and DP-EES in patients aged ≥80 years.
METHODS: We retrospectively analyzed 213 patients aged ≥80 years who underwent percutaneous coronary intervention (PCI) with BP-SES or DP-EES between April 2020 and March 2022. The primary endpoint was a 1-year composite of all-cause death, MI, target vessel revascularization (TVR), cerebrovascular accident (CVA), and definite or probable stent thrombosis (ST). To minimize stent selection bias, propensity score matching was conducted. Multivariable logistic regression was used to identify factors associated with the 1-year primary endpoint in the matched cohort.
RESULTS: Among 213 patients treated with BP-SES (n = 93) and DP-EES (n = 120), the 1-year rates of MI, TVR, CVA, ST, and bleeding events were similar between the two groups. After propensity score matching, 1-year event-free survival for the primary endpoint was similar between the BP-SES and DP-EES groups [hazard ratio, 0.893; 95% confidence interval (CI), 0.345-2.315; p = 0.816]. Multivariable analysis demonstrated that acute coronary syndrome [odds ratio (OR), 3.478; 95% CI, 1.019-14.190; p = 0.047] was independently associated with a higher incidence of the 1-year primary endpoint, whereas angiographic success (OR, 0.058; 95% CI, 0.008-0.347; p = 0.002) and angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor blocker use at discharge (OR, 0.229; 95% CI, 0.057-0.858; p = 0.029) were independently associated with a lower incidence.
CONCLUSIONS: In patients aged ≥80 years, 1-year clinical outcomes after PCI with BP-SES were generally consistent with those with DP-EES.
METHODS: We retrospectively analyzed 213 patients aged ≥80 years who underwent percutaneous coronary intervention (PCI) with BP-SES or DP-EES between April 2020 and March 2022. The primary endpoint was a 1-year composite of all-cause death, MI, target vessel revascularization (TVR), cerebrovascular accident (CVA), and definite or probable stent thrombosis (ST). To minimize stent selection bias, propensity score matching was conducted. Multivariable logistic regression was used to identify factors associated with the 1-year primary endpoint in the matched cohort.
RESULTS: Among 213 patients treated with BP-SES (n = 93) and DP-EES (n = 120), the 1-year rates of MI, TVR, CVA, ST, and bleeding events were similar between the two groups. After propensity score matching, 1-year event-free survival for the primary endpoint was similar between the BP-SES and DP-EES groups [hazard ratio, 0.893; 95% confidence interval (CI), 0.345-2.315; p = 0.816]. Multivariable analysis demonstrated that acute coronary syndrome [odds ratio (OR), 3.478; 95% CI, 1.019-14.190; p = 0.047] was independently associated with a higher incidence of the 1-year primary endpoint, whereas angiographic success (OR, 0.058; 95% CI, 0.008-0.347; p = 0.002) and angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor blocker use at discharge (OR, 0.229; 95% CI, 0.057-0.858; p = 0.029) were independently associated with a lower incidence.
CONCLUSIONS: In patients aged ≥80 years, 1-year clinical outcomes after PCI with BP-SES were generally consistent with those with DP-EES.